In vivo models of cardiac diseases: application to drug development and screening

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Opinion on Drug Discovery

• Publication date

  2010-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17460440903460299PMID 22823972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modelos animales de enfermedad cardiovascular

  2009cited by this paper
• Atrial fibrillation: cure or treat?

  2009cited by this paper
• Contemporary treatment of hypertrophic cardiomyopathy.

  2009cited by this paper
• Cardiac cachexia: a systematic overview.

  2009cited by this paper
• [Animal models of cardiovascular disease].

  2009cited by this paper
• Sudden cardiac death: Prevalence, pathogenesis, and prevention

  2008cited by this paper
• Zebrafish genetic models for arrhythmia.

  2008cited by this paper
• Modeling cardiovascular disease in the zebrafish.

  2008influential reference
• The canine model with chronic, complete atrio-ventricular block.

  2008cited by this paper
• Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery

  2008cited by this paper
• Mouse models of human arrhythmia syndromes

  2008cited by this paper
• Ex vivo and in vivo approaches to study mechanisms of cardioprotection targeting ischemia/reperfusion (i/r) injury: useful techniques for cardiovascular drug discovery.

  2008cited by this paper
• Sensitive and reliable proarrhythmia in vivo animal models for predicting drug‐induced torsades de pointes in patients with remodelled hearts

  2008cited by this paper
• Acute myocardial infarction

  2008cited by this paper
• Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat.

  2008cited by this paper
• Vasopressin and epinephrine in the treatment of cardiac arrest: an experimental study

  2008cited by this paper
• Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.

  2008cited by this paper
• Evaluation of zebrafish embryos as a model for assessing inhibition of hERG.

  2008cited by this paper
• Model systems for the discovery and development of antiarrhythmic drugs.

  2008influential reference
• Pharmacologic therapeutics for cardiac reperfusion injury

  2007cited by this paper
• Mouse models for atherosclerosis and pharmaceutical modifiers.

  2007influential reference
• Knockin Animal Models of Inherited Arrhythmogenic Diseases: What Have We Learned From Them?

  2007cited by this paper
• The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy.

  2007cited by this paper
• Rodent models of heart failure.

  2007influential reference
• Animal models of ventricular arrhythmias.

  2007influential reference
• Protective Effects of Parecoxib, a Cyclo-Oxygenase-2 Inhibitor, in Postinfarction Remodeling in the Rat

  2007cited by this paper
• HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo‐controlled pilot study

  2007cited by this paper
• Animal Models of Dilated Cardiomyopathy for Translational Research

  2007influential reference
• MR in mouse models of cardiac disease

  2007cited by this paper
• Drug administration in animal studies of cardiac arrest does not reflect human clinical experience.

  2007cited by this paper
• Arrhythmia models for drug research: classification of antiarrhythmic drugs.

  2007cited by this paper
• Selective Cyclooxygenase-2 Inhibition With Celecoxib Decreases Angiotensin II–Induced Abdominal Aortic Aneurysm Formation in Mice

  2006cited by this paper
• Preclinical Restenosis Models: Challenges and Successes

  2006cited by this paper
• In vitro and in vivo models for testing arrhythmogenesis in drugs

  2006cited by this paper
• Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.

  2006cited by this paper
• Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis.

  2006cited by this paper
• The minipig in toxicology.

  2006cited by this paper
• Rat models of myocardial infarction

  2006cited by this paper
• Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure.

  2006influential reference
• Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats.

  2006cited by this paper
• Histologic Characterization of Canine Dilated Cardiomyopathy

  2005cited by this paper
• Transgenic Rabbit Model for Human Troponin I–Based Hypertrophic Cardiomyopathy

  2005cited by this paper
• Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure.

  2005cited by this paper
• Animal models of heart failure: what is new?

  2005influential reference
• Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals?

  2005cited by this paper
• A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload.

  2005cited by this paper
• A novel method for safe and accurate left anterior descending coronary artery ligation for research in rats.

  2005cited by this paper
• Learning from failure: congestive heart failure in the postgenomic age.

  2005cited by this paper
• Mechanisms of atrial fibrillation: lessons from animal models.

  2005cited by this paper
• Laboratory animals: The Renaissance rat

  2004cited by this paper
• Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy

  2004cited by this paper
• Apolipoprotein E and atherosclerosis: beyond lipid effect.

  2004cited by this paper
• A novel minimal-invasive model of chronic myocardial infarction in swine

  2004cited by this paper
• Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27

  2004cited by this paper
• Atrial Fibrillation in Rats Induced by Rapid Transesophageal Atrial Pacing during Brief Episodes of Asphyxia: A New In Vivo Model

  2004cited by this paper
• Myocardial infarction: animal models.

  2004cited by this paper
• “Early” Class III Drugs for the Treatment of Atrial Fibrillation: Efficacy and Atrial Selectivity of AVE0118 in Remodeled Atria of the Goat

  2004cited by this paper
• A Murine Model of Ischemic Cardiomyopathy Induced by Repetitive Ischemia and Reperfusion*

  2004cited by this paper
• Use of animals in experimental research: an ethical dilemma?

  2004cited by this paper
• Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation

  2004cited by this paper
• Mouse models of experimental atherosclerosis.

  2004cited by this paper
• Murine models for the study of congestive heart failure: Implications for understanding molecular mechanisms and for drug discovery.

  2004influential reference
• Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes

  2004cited by this paper
• Effects of long-term captopril and L-arginine treatment on ventilation and blood pressure in obese male SHHF rats.

  2004cited by this paper
• Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease.

  2004cited by this paper
• Induction of Chronic Cardiac Insufficiency by Arteriovenous Fistula and Doxorubicin Administration

  2003cited by this paper
• Heart failure.

  2003cited by this paper
• Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish

  2003cited by this paper
• New ideas about atrial fibrillation 50 years on

  2002cited by this paper
• Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E-Deficient Mice

  2002cited by this paper
• Hypertrophic cardiomyopathy: a systematic review.

  2002cited by this paper
• Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile.

  2002cited by this paper
• Dilated cardiomyopathy: concepts derived from gene deficient and transgenic animal models.

  2002cited by this paper
• Progressive heart failure after myocardial infarction in mice

  2002cited by this paper
• Functional recovery of the native heart after cardiomyoplasty in sheep with heart failure: passive and dynamic effects of volume loading.

  2002cited by this paper
• Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats.

  2002cited by this paper
• Dynamic Nature of Atrial Fibrillation Substrate During Development and Reversal of Heart Failure in Dogs

  2002cited by this paper
• Induction and maintenance of an experimental model of severe cardiomyopathy with a novel protocol of rapid ventricular pacing.

  2002cited by this paper
• Muscle LIM protein in heart failure.

  2002cited by this paper
• An ovine model of postinfarction dilated cardiomyopathy.

  2002cited by this paper
• Cardiac Arrhythmias: From (Transgenic) Mice to Men

  2001cited by this paper
• Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy

  2001cited by this paper
• Severe Hypercholesterolemia, Hypertriglyceridemia, and Atherosclerosis in Mice Lacking Both Leptin and the Low Density Lipoprotein Receptor*

  2001cited by this paper
• Cellular therapy reverses myocardial dysfunction.

  2001cited by this paper
• Chronic Administration of Ghrelin Improves Left Ventricular Dysfunction and Attenuates Development of Cardiac Cachexia in Rats With Heart Failure

  2001cited by this paper
• In vivo models of myocardial metabolism during ischemia: application to drug discovery and evaluation.

  2000cited by this paper
• Transmural Heterogeneity of Ventricular Repolarization Under Baseline and Long QT Conditions in the Canine Heart In Vivo: Torsades de Pointes Develops with Halothane but not Pentobarbital Anesthesia

  2000cited by this paper
• Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy

  2000cited by this paper
• Anthracycline-induced cardiotoxicity.

  2000cited by this paper
• Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation.

  2000cited by this paper
• Animal models of chronic heart failure.

  2000influential reference
• The ischemic heart--experimental models.

  2000cited by this paper
• Animal models of hypertrophic cardiomyopathy.

  2000cited by this paper
• Experimental models for the study of cardiovascular function and disease.

  2000influential reference
• Response of aorta connective tissue matrix to injury caused by vassopressin-induced hypertension or hypercholesterolemia.

  2000cited by this paper
• Models of dilated cardiomyopathy in the mouse and the hamster.

  2000cited by this paper
• Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure.

  1999cited by this paper
• Effects of Growth Hormone and Angiotensin-Converting Enzyme Inhibition Progressive Cardiac Dysfunction and Fibrosis in the Cardiomyopathic Hamster and

  1999cited by this paper
• A transgenic rabbit model for human hypertrophic cardiomyopathy.

  1999cited by this paper
• Effects of cardiomyoplasty on right ventricular filling during volume loading.

  1998cited by this paper

• In Vivo Efficacy of an Adhesive Bioresorbable Patch to Treat Aortic Dissections

  2023cites this paper
• The screening toolbox of bioactive substances from natural products: a review.

  2011cites this paper